title: Ipilimumab-induced necrotic myelopathy in a patient with metastatic melanoma: A case report and review of literature.
abstract: Ipilimumab is a novel humanized monoclonal antibody directed against cytotoxic T lymphocyte antigen 4, a T-cell surface molecule involved in down-regulation and suppression of the T cell response to stimuli. Patients treated with ipilimumab are at risk for immune-related adverse events involving the skin, digestive tract, liver and endocrine organs. Few case reports of immune-related adverse effects involving central or peripheral nervous system due to ipilimumab are published. These include inflammatory myopathy, aseptic meningitis, severe meningo-radiculo-neuritis, temporal arteritis, Guillain-Barre syndrome, and posterior reversible encephalopathy syndrome. We report the first case of ipilimumab-induced progressive necrotic myelopathy.
authors.affiliation: Department of Internal Medicine, Division of Hematology and Oncology, University of Arkansas for Medical Sciences (UAMS), Little Rock, AR, USA.
authors.forename: Al-Ola
authors.initials: AO
authors.lastname: Abdallah
authors.affiliation: Department of Internal Medicine, Division of Neurology, University of Arkansas for Medical Sciences (UAMS), Little Rock, AR, USA.
authors.forename: Aline
authors.initials: A
authors.lastname: Herlopian
authors.affiliation: Department of Internal Medicine, University of Arkansas for Medical Sciences (UAMS), Little Rock, AR, USA.
authors.forename: Rahul
authors.initials: R
authors.lastname: Ravilla
authors.affiliation: Department of Internal Medicine, Division of Hematology and Oncology, University of Arkansas for Medical Sciences (UAMS), Little Rock, AR, USA.
authors.forename: Meghana
authors.initials: M
authors.lastname: Bansal
authors.affiliation: Department of Internal Medicine, University of Arkansas for Medical Sciences (UAMS), Little Rock, AR, USA.
authors.forename: Sowmya
authors.initials: S
authors.lastname: Chandra-Reddy
authors.affiliation: Department of Internal Medicine, Division of Hematology and Oncology, University of Arkansas for Medical Sciences (UAMS), Little Rock, AR, USA.
authors.forename: Fade
authors.initials: F
authors.lastname: Mahmoud
authors.affiliation: Department of Internal Medicine, Division of Neurology, University of Arkansas for Medical Sciences (UAMS), Little Rock, AR, USA.
authors.forename: Shirley
authors.initials: S
authors.lastname: Ong
authors.affiliation: Department of Pathology, University of Arkansas for Medical Sciences (UAMS), Little Rock, AR, USA.
authors.forename: Murat
authors.initials: M
authors.lastname: Gokden
authors.affiliation: Department of Internal Medicine, Division of Hematology and Oncology, University of Arkansas for Medical Sciences (UAMS), Little Rock, AR, USA HutchinsLauraF@uams.edu.
authors.forename: Laura
authors.initials: L
authors.lastname: Hutchins
mesh_terms: D000074322:Antineoplastic Agents, Immunological / Q000009:adverse effects*; D005260:Female; D006801:Humans; D000074324:Ipilimumab / Q000009:adverse effects*; D008545:Melanoma / Q000000981:diagnostic imaging / Q000188:drug therapy*; D008875:Middle Aged; D010020:Osteonecrosis / Q000139:chemically induced* / Q000000981:diagnostic imaging; D012878:Skin Neoplasms / Q000000981:diagnostic imaging / Q000188:drug therapy*; D013118:Spinal Cord Diseases / Q000139:chemically induced* / Q000000981:diagnostic imaging
chemical_list: D000074322:Antineoplastic Agents, Immunological; D000074324:Ipilimumab
keywords: Ipilimumab; immune-related adverse events; progressive necrotic myelopathy